Monjuvi (Tafasitamab-cxix) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Monjuvi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with refractory or relapsed diffuse large B-cell lymphoma (DLBCL) not otherwise specified in people who are not eligible for an autologous stem cell transplant. Monjuvi is given with lenalidomide. Monjuvi is also referred to by its drug name, tafasitamab-cxix.

Monjuvi is a member of a class of drugs called cytolytic monoclonal antibodies. Monjuvi is believed to work by destroying cancer cells.

How do I take it?
Prescribing information states that Monjuvi is administered intravenously in cycles that vary in timing, for up to 12 cycles.

Monjuvi comes in the form of an injection.

Side effects
The FDA-approved label for Monjuvi lists common side effects including low blood counts, fatigue, fever, swelling, diarrhea, constipation, nausea, vomiting, cough, respiratory infection, decreased appetite, and back pain.

Rare but serious side effects listed for Monjuvi include infusion-related reactions, severely low blood counts, infections, and fetal harm in pregnant women.

For more details about this treatment, visit:

Monjuvi — RxList

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in